2024-510774-24-00
已完成
1 期
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Adamed Pharma S.A.
- 入组人数
- 30
- 试验地点
- 1
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
Pharmacokinetic Study Team
Scientific
Adamed Pharma S.A.
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (1)
Loading locations...
相似试验
已完成
1 期
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.2023-507991-32-00Sun Pharmaceutical Industries Limited32
招募中
1 期
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes2025-523879-34-00Swedish Match North Europe AB72
尚未招募
1 期
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.2025-522921-37-00Gebro Pharma GmbH36
尚未招募
1 期
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.2025-524035-39-00Laboratorios Cinfa S.A.32
已完成
1 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56